-
1
-
-
40749159213
-
Quantifying the risk for alcohol-use and alcoholattributable health disorders: Present findings and future research needs
-
Li TK. Quantifying the risk for alcohol-use and alcoholattributable health disorders: present findings and future research needs. J Gastroenterol Hepatol 2008; 23 Suppl 1: S2-S8
-
(2008)
J Gastroenterol Hepatol
, vol.23
, Issue.SUPPL. 1.
-
-
Li, T.K.1
-
2
-
-
0034627156
-
The effect of ethanol-induced cytochrome p4502E1 on the inhibition of proteasome activity by alcohol
-
Bardag-Gorce F, Yuan QX, Li J, French BA, Fang C, Ingelman- Sundberg M, French SW. The effect of ethanol-induced cytochrome p4502E1 on the inhibition of proteasome activity by alcohol. Biochem Biophys Res Commun 2000; 279: 23-29
-
(2000)
Biochem Biophys Res Commun
, vol.279
, pp. 23-29
-
-
Bardag-Gorce, F.1
Yuan, Q.X.2
Li, J.3
French, B.A.4
Fang, C.5
Ingelman- sundberg, M.6
French, S.W.7
-
3
-
-
0035998920
-
Effects of alcohol and oxidative stress on liver pathology: The role of the mitochondrion
-
Cahill A, Cunningham CC, Adachi M, Ishii H, Bailey SM, Fromenty B, Davies A. Effects of alcohol and oxidative stress on liver pathology: the role of the mitochondrion. Alcohol Clin Exp Res 2002; 26: 907-915
-
(2002)
Alcohol Clin Exp Res
, vol.26
, pp. 907-915
-
-
Cahill, A.1
Cunningham, C.C.2
Adachi, M.3
Ishii, H.4
Bailey, S.M.5
Fromenty, B.6
Davies, A.7
-
4
-
-
33745755554
-
Chronic ethanol feeding increases activation of NADPH oxidase by lipopolysaccharide in rat Kupffer cells: Role of increased reactive oxygen in LPS-stimulated ERK1/2 activation and TNF-alpha production
-
Thakur V, Pritchard MT, McMullen MR, Wang Q, Nagy LE. Chronic ethanol feeding increases activation of NADPH oxidase by lipopolysaccharide in rat Kupffer cells: role of increased reactive oxygen in LPS-stimulated ERK1/2 activation and TNF-alpha production. J Leukoc Biol 2006; 79: 1348-1356
-
(2006)
J Leukoc Biol
, vol.79
, pp. 1348-1356
-
-
Thakur, V.1
Pritchard, M.T.2
McMullen, M.R.3
Wang, Q.4
Nagy, L.E.5
-
5
-
-
33645771481
-
Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: Involvement of JNK and ERK MAP kinases
-
Conde de la Rosa L L, Schoemaker MH, Vrenken TE, Buist-Homan M, Havinga R, Jansen PL, Moshage H. Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: involvement of JNK and ERK MAP kinases. J Hepatol 2006; 44: 918-929
-
(2006)
J Hepatol
, vol.44
, pp. 918-929
-
-
Conde de la Rosa L, L.1
Schoemaker, M.H.2
Vrenken, T.E.3
Buist-Homan, M.4
Havinga, R.5
Jansen, P.L.6
Moshage, H.7
-
6
-
-
0036139102
-
Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species
-
Nieto N, Friedman SL, Cederbaum AI. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology 2002; 35: 62-73
-
(2002)
Hepatology
, vol.35
, pp. 62-73
-
-
Nieto, N.1
Friedman, S.L.2
Cederbaum, A.I.3
-
7
-
-
0034615999
-
p-hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima
-
Heller JI, Crowley JR, Hazen SL, Salvay DM, Wagner P, Pennathur S, Heinecke JW. p-hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima. J Biol Chem 2000; 275: 9957-9962
-
(2000)
J Biol Chem
, vol.275
, pp. 9957-9962
-
-
Heller, J.I.1
Crowley, J.R.2
Hazen, S.L.3
Salvay, D.M.4
Wagner, P.5
Pennathur, S.6
Heinecke, J.W.7
-
8
-
-
3042802690
-
Glutathione: An overview of biosynthesis and modulation
-
Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 1998; 111-112: 1-14
-
(1998)
Chem Biol Interact
, vol.111-112
, pp. 1-14
-
-
Anderson, M.E.1
-
9
-
-
0034955787
-
Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes
-
Hammond CL, Lee TK, Ballatori N. Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes. J Hepatol 2001; 34: 946-954
-
(2001)
J Hepatol
, vol.34
, pp. 946-954
-
-
Hammond, C.L.1
Lee, T.K.2
Ballatori, N.3
-
10
-
-
0344393732
-
Strategies for reversing drug resistance
-
Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003; 22: 7512-7523
-
(2003)
Oncogene
, vol.22
, pp. 7512-7523
-
-
Fojo, T.1
Bates, S.2
-
11
-
-
27744540258
-
Marked differences in the efficacy of post-insult gene therapy with catalase versus glutathione peroxidase
-
Chang P, Cheng E, Brooke S, Sapolsky R. Marked differences in the efficacy of post-insult gene therapy with catalase versus glutathione peroxidase. Brain Res 2005; 1063: 27-31
-
(2005)
Brain Res
, vol.1063
, pp. 27-31
-
-
Chang, P.1
Cheng, E.2
Brooke, S.3
Sapolsky, R.4
-
12
-
-
20044396543
-
study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
-
Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667-675
-
(2005)
J Clin Oncol
, vol.23
, pp. 667-675
-
-
Goy, A.1
Younes, A.2
McLaughlin, P.3
Pro, B.4
Romaguera, J.E.5
Hagemeister, F.6
Fayad, L.7
Dang, N.H.8
Samaniego, F.9
Wang, M.10
Broglio, K.11
Samuels, B.12
Gilles, F.13
Sarris, A.H.14
Hart, S.15
Trehu, E.16
Schenkein, D.17
Cabanillas, F.18
Rodriguez, A.M.19
Phase, I.I.20
more..
-
13
-
-
0030860079
-
GSH transport in mitochondria: Defense against TNF-induced oxidative stress and alcohol-induced defect
-
Fernández-Checa JC, Kaplowitz N, García-Ruiz C, Colell A,Miranda M, Marí M, Ardite E, Morales A. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol 1997; 273: G7-G17
-
(1997)
Am J Physiol
, vol.273
-
-
Fernández-Checa, J.C.1
Kaplowitz, N.2
García-Ruiz, C.3
Colell, A.4
Miranda, M.5
Marí, M.6
Ardite, E.7
Morales, A.8
-
14
-
-
0034465251
-
Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial
-
Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648
-
(2000)
Gastroenterology
, vol.119
, pp. 1637-1648
-
-
Akriviadis, E.1
Botla, R.2
Briggs, W.3
Han, S.4
Reynolds, T.5
Shakil, O.6
-
15
-
-
2342502025
-
A doubleblind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis
-
Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A doubleblind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397
-
(2004)
Hepatology
, vol.39
, pp. 1390-1397
-
-
Naveau, S.1
Chollet-Martin, S.2
Dharancy, S.3
Mathurin, P.4
Jouet, P.5
Piquet, M.A.6
Davion, T.7
Oberti, F.8
Broët, P.9
Emilie, D.10
-
16
-
-
57249086241
-
A randomized, double-blinded, placebocontrolled multicenter trial of etanercept in the treatment of alcoholic hepatitis
-
Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, Mc Clain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebocontrolled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-1960
-
(2008)
Gastroenterology
, vol.135
, pp. 1953-1960
-
-
Boetticher, N.C.1
Peine, C.J.2
Kwo, P.3
Abrams, G.A.4
Patel, T.5
Aqel, B.6
Boardman, L.7
Gores, G.J.8
Harmsen, W.S.9
Mc Clain, C.J.10
Kamath, P.S.11
Shah, V.H.12
-
17
-
-
0347950972
-
A randomized placebo controlled trial of vitamin E for alcoholic hepatitis
-
Mezey E, Potter JJ, Rennie-Tankersley L, Caballeria J, Pares A. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004; 40: 40-46
-
(2004)
J Hepatol
, vol.40
, pp. 40-46
-
-
Mezey, E.1
Potter, J.J.2
Rennie-Tankersley, L.3
Caballeria, J.4
Pares, A.5
-
18
-
-
34347401402
-
A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis
-
Stewart S, Prince M, Bassendine M, Hudson M, James O, Jones D, Record C, Day CP. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007; 47: 277-283
-
(2007)
J Hepatol
, vol.47
, pp. 277-283
-
-
Stewart, S.1
Prince, M.2
Bassendine, M.3
Hudson, M.4
James, O.5
Jones, D.6
Record, C.7
Day, C.P.8
-
19
-
-
0025297895
-
Disulfiram treatment of alcoholism
-
Wright C, Moore RD. Disulfiram treatment of alcoholism. Am J Med 1990; 88: 647-655
-
(1990)
Am J Med
, vol.88
, pp. 647-655
-
-
Wright, C.1
Moore, R.D.2
-
20
-
-
48149090212
-
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
-
Cvek B, Dvorak Z. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discov Today 2008; 13: 716-722
-
(2008)
Drug Discov Today
, vol.13
, pp. 716-722
-
-
Cvek, B.1
Dvorak, Z.2
-
21
-
-
33845304732
-
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients
-
Wickström M, Danielsson K, Rickardson L, Gullbo J, Nygren P, Isaksson A, Larsson R, Lövborg H. Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem Pharmacol 2007; 73: 25-33
-
(2007)
Biochem Pharmacol
, vol.73
, pp. 25-33
-
-
Wickström, M.1
Danielsson, K.2
Rickardson, L.3
Gullbo, J.4
Nygren, P.5
Isaksson, A.6
Larsson, R.7
Lövborg, H.8
-
22
-
-
33845668472
-
Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells
-
Naujokat C, Berges C, Höh A, Wieczorek H, Fuchs D, Ovens J, Miltz M, Sadeghi M, Opelz G, Daniel V. Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells. Immunology 2007; 120: 120-132
-
(2007)
Immunology
, vol.120
, pp. 120-132
-
-
Naujokat, C.1
Berges, C.2
Höh, A.3
Wieczorek, H.4
Fuchs, D.5
Ovens, J.6
Miltz, M.7
Sadeghi, M.8
Opelz, G.9
Daniel, V.10
-
23
-
-
9644289334
-
The proteasome and MHC class I antigen processing
-
Kloetzel PM. The proteasome and MHC class I antigen processing. Biochim Biophys Acta 2004; 1695: 225-233
-
(2004)
Biochim Biophys Acta
, vol.1695
, pp. 225-233
-
-
Kloetzel, P.M.1
-
24
-
-
33845306274
-
Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis
-
Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, Kaufmann SH, Schmidt-Ullrich R, Steinhoff U. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 2006; 116: 3195-3203
-
(2006)
J Clin Invest
, vol.116
, pp. 3195-3203
-
-
Visekruna, A.1
Joeris, T.2
Seidel, D.3
Kroesen, A.4
Loddenkemper, C.5
Zeitz, M.6
Kaufmann, S.H.7
Schmidt-Ullrich, R.8
Steinhoff, U.9
-
25
-
-
61449206184
-
The persisting challenge of selective and specific proteasome inhibition
-
Groll M, Huber R, Moroder L. The persisting challenge of selective and specific proteasome inhibition. J Pept Sci 2009; 15: 58-66
-
(2009)
J Pept Sci
, vol.15
, pp. 58-66
-
-
Groll, M.1
Huber, R.2
Moroder, L.3
-
26
-
-
60749114007
-
Proteasome inhibition: A promising strategy for treating cancer, but what about neurotoxicity?
-
Gilardini A, Marmiroli P, Cavaletti G. Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity? Curr Med Chem 2008; 15: 3025-3035
-
(2008)
Curr Med Chem
, vol.15
, pp. 3025-3035
-
-
Gilardini, A.1
Marmiroli, P.2
Cavaletti, G.3
-
27
-
-
54249154594
-
Targeting the UPS as therapy in multiple myeloma
-
Chauhan D, Bianchi G, Anderson KC. Targeting the UPS as therapy in multiple myeloma. BMC Biochem 2008; 9 Suppl 1: S1
-
(2008)
BMC Biochem
, vol.9
, Issue.SUPPL. 1.
-
-
Chauhan, D.1
Bianchi, G.2
Anderson, K.C.3
-
28
-
-
0037973279
-
A phase 2 study of bortezomib in relapsed, refractory myeloma
-
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617
-
(2003)
N Engl J Med
, vol.348
, pp. 2609-2617
-
-
Richardson, P.G.1
Barlogie, B.2
Berenson, J.3
Singhal, S.4
Jagannath, S.5
Irwin, D.6
Rajkumar, S.V.7
Srkalovic, G.8
Alsina, M.9
Alexanian, R.10
Siegel, D.11
Orlowski, R.Z.12
Kuter, D.13
Limentani, S.A.14
Lee, S.15
Hideshima, T.16
Esseltine, D.L.17
Kauffman, M.18
Adams, J.19
Schenkein, D.P.20
Anderson, K.C.21
more..
-
29
-
-
0346692671
-
Bortezomib (millennium pharmaceuticals
-
Dou QP, Goldfarb RH. Bortezomib (millennium pharmaceuticals). IDrugs 2002; 5: 828-834
-
(2002)
IDrugs
, vol.5
, pp. 828-883
-
-
Dou, Q.P.1
Goldfarb, R.H.2
-
30
-
-
2442510143
-
Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study
-
Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004; 22: 115-119
-
(2004)
J Clin Oncol
, vol.22
, pp. 115-119
-
-
Davis, N.B.1
Taber, D.A.2
Ansari, R.H.3
Ryan, C.W.4
George, C.5
Vokes, E.E.6
Vogelzang, N.J.7
Stadler, W.M.8
-
31
-
-
4644304196
-
Phase II trial of bortezomib for patients with advanced renal cell carcinoma
-
Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22: 3720-3725
-
(2004)
J Clin Oncol
, vol.22
, pp. 3720-3725
-
-
Kondagunta, G.V.1
Drucker, B.2
Schwartz, L.3
Bacik, J.4
Marion, S.5
Russo, P.6
Mazumdar, M.7
Motzer, R.J.8
Phase, I.I.9
-
32
-
-
4644248931
-
Phase II study study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors
-
Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004; 10: 6111-6118
-
(2004)
Clin Cancer Res
, vol.10
, pp. 6111-6118
-
-
Shah, M.H.1
Young, D.2
Kindler, H.L.3
Webb, I.4
Kleiber, B.5
Wright, J.6
Grever, M.7
Phase, I.I.8
-
33
-
-
2942692143
-
Phase I trial of the trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
-
Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-2121
-
(2004)
J Clin Oncol
, vol.22
, pp. 2108-2121
-
-
Papandreou, C.N.1
Daliani, D.D.2
Nix, D.3
Yang, H.4
Madden, T.5
Wang, X.6
Pien, C.S.7
Millikan, R.E.8
Tu, S.M.9
Pagliaro, L.10
Kim, J.11
Adams, J.12
Elliott, P.13
Esseltine, D.14
Petrusich, A.15
Dieringer, P.16
Perez, C.17
Logothetis, C.J.18
Phase, I.19
-
34
-
-
33646058316
-
Intracellular distribution of oxidized proteins and proteasome in HT22 cells during oxidative stress
-
Jung T, Engels M, Kaiser B, Poppek D, Grune T. Intracellular distribution of oxidized proteins and proteasome in HT22 cells during oxidative stress. Free Radic Biol Med 2006; 40: 1303-1312
-
(2006)
Free Radic Biol Med
, vol.40
, pp. 1303-1312
-
-
Jung, T.1
Engels, M.2
Kaiser, B.3
Poppek, D.4
Grune, T.5
-
35
-
-
35848935847
-
Regulation of ubiquitinproteasome system mediated degradation by cytosolic stress
-
Kelly SM, Vanslyke JK, Musil LS. Regulation of ubiquitinproteasome system mediated degradation by cytosolic stress. Mol Biol Cell 2007; 18: 4279-4291
-
(2007)
Mol Biol Cell
, vol.18
, pp. 4279-4291
-
-
Kelly, S.M.1
Vanslyke, J.K.2
Musil, L.S.3
-
36
-
-
33947517977
-
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: Relevance to Parkinson disease
-
Yamamoto N, Sawada H, Izumi Y, Kume T, Katsuki H, Shimohama S, Akaike A. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem 2007; 282: 4364-4372
-
(2007)
J Biol Chem
, vol.282
, pp. 4364-4372
-
-
Yamamoto, N.1
Sawada, H.2
Izumi, Y.3
Kume, T.4
Katsuki, H.5
Shimohama, S.6
Akaike, A.7
-
37
-
-
33746809848
-
Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: Relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration
-
Williams AJ, Dave JR, Tortella FC. Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration. Neurochem Int 2006; 49: 106-112
-
(2006)
Neurochem Int
, vol.49
, pp. 106-112
-
-
Williams, A.J.1
Dave, J.R.2
Tortella, F.C.3
-
38
-
-
33845520806
-
Proteasome inhibitors: Antitumor effects and beyond
-
Nencioni A, Grünebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007; 21: 30-36
-
(2007)
Leukemia
, vol.21
, pp. 30-36
-
-
Nencioni, A.1
Grünebach, F.2
Patrone, F.3
Ballestrero, A.4
Brossart, P.5
-
39
-
-
67349205896
-
Proteasome inhibition prevents experimentally- induced endothelial dysfunction
-
Lorenz M, Wilck N, Meiners S, Ludwig A, Baumann G, Stangl K, Stangl V. Proteasome inhibition prevents experimentally- induced endothelial dysfunction. Life Sci 2009; 84: 929-934
-
(2009)
Life Sci
, vol.84
, pp. 929-934
-
-
Lorenz, M.1
Wilck, N.2
Meiners, S.3
Ludwig, A.4
Baumann, G.5
Stangl, K.6
Stangl, V.7
-
40
-
-
34548289851
-
Role of the proteasome in ethanol-induced liver pathology
-
Donohue TM, Cederbaum AI, French SW, Barve S, Gao B, Osna NA. Role of the proteasome in ethanol-induced liver pathology. Alcohol Clin Exp Res 2007; 31: 1446-1459
-
(2007)
Alcohol Clin Exp Res
, vol.31
, pp. 1446-1459
-
-
Donohue, T.M.1
Cederbaum, A.I.2
French, S.W.3
Barve, S.4
Gao, B.5
Osna, N.A.6
-
41
-
-
0035138847
-
Intragastric ethanol infusion model for cellular and molecular studies of alcoholic liver disease
-
French SW. Intragastric ethanol infusion model for cellular and molecular studies of alcoholic liver disease. J Biomed Sci 2001; 8: 20-27
-
(2001)
J Biomed Sci
, vol.8
, pp. 20-27
-
-
French, S.W.1
-
42
-
-
0037090225
-
Free radicals in alcoholic myopathy: Indices of damage and preventive studies
-
Preedy VR, Adachi J, Asano M, Koll M, Mantle D, Niemela O, Parkkila S, Paice AG, Peters T, Rajendram R, Seitz H, Ueno Y, Worrall S. Free radicals in alcoholic myopathy: indices of damage and preventive studies. Free Radic Biol Med 2002; 32: 683-687
-
(2002)
Free Radic Biol Med
, vol.32
, pp. 683-687
-
-
Preedy, V.R.1
Adachi, J.2
Asano, M.3
Koll, M.4
Mantle, D.5
Niemela, O.6
Parkkila, S.7
Paice, A.G.8
Peters, T.9
Rajendram, R.10
Seitz, H.11
Ueno, Y.12
Worrall, S.13
-
43
-
-
0033872080
-
Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole
-
Gouillon Z, Lucas D, Li J, Hagbjork AL, French BA, Fu P, Fang C, Ingelman-Sundberg M, Donohue TM, French SW. Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole. Proc Soc Exp Biol Med 2000; 224: 302-308
-
(2000)
Proc Soc Exp Biol Med
, vol.224
, pp. 302-308
-
-
Gouillon, Z.1
Lucas, D.2
Li, J.3
Hagbjork, A.L.4
French, B.A.5
Fu, P.6
Fang, C.7
Ingelman-Sundberg, M.8
Donohue, T.M.9
French, S.W.10
-
44
-
-
67651233454
-
Chronic ethanol feeding affects proteasome-interacting proteins
-
Bousquet-Dubouch MP, Nguen S, Bouyssié D, Burlet-Schiltz O, French SW, Monsarrat B, Bardag-Gorce F. Chronic ethanol feeding affects proteasome-interacting proteins. Proteomics 2009; 9: 3609-3622
-
(2009)
Proteomics
, vol.9
, pp. 3609-3622
-
-
Bousquet-Dubouch, M.P.1
Nguen, S.2
Bouyssié, D.3
Burlet-schiltz, O.4
French, S.W.5
Monsarrat, B.6
Bardag-Gorce, F.7
-
45
-
-
65649100057
-
Epigenetics of proteasome inhibition in the liver of rats fed ethanol chronically
-
Oliva J, Dedes J, Li J, French SW, Bardag-Gorce F. Epigenetics of proteasome inhibition in the liver of rats fed ethanol chronically. World J Gastroenterol 2009; 15: 705-712
-
(2009)
World J Gastroenterol
, vol.15
, pp. 705-712
-
-
Oliva, J.1
Dedes, J.2
Li, J.3
French, S.W.4
Bardag-Gorce, F.5
-
46
-
-
53249091920
-
Diallyl trisulfide (DATS) effectively attenuated oxidative stressmediated liver injury and hepatic mitochondrial dysfunction in acute ethanol-exposed mice
-
Zeng T, Zhang CL, Zhu ZP, Yu LH, Zhao XL, Xie KQ. Diallyl trisulfide (DATS) effectively attenuated oxidative stressmediated liver injury and hepatic mitochondrial dysfunction in acute ethanol-exposed mice. Toxicology 2008; 252: 86-91
-
(2008)
Toxicology
, vol.252
, pp. 86-91
-
-
Zeng, T.1
Zhang, C.L.2
Zhu, Z.P.3
Yu, L.H.4
Zhao, X.L.5
Xie, K.Q.6
-
47
-
-
34250824010
-
Alcohol-induced oxidative stress
-
Das SK, Vasudevan DM. Alcohol-induced oxidative stress. Life Sci 2007; 81: 177-187
-
(2007)
Life Sci
, vol.81
, pp. 177-187
-
-
Das, S.K.1
Vasudevan, D.M.2
-
48
-
-
78650710068
-
Proteasome inhibitor up regulates liver antioxidative en-zymes in rat model of alcoholic liver disease
-
Bardag-Gorce F, Oliva J, Lin A, Li J, French BA, French SW. Proteasome inhibitor up regulates liver antioxidative en-zymes in rat model of alcoholic liver disease. Exp Mol Pathol 2011; 90: 123-130
-
(2011)
Exp Mol Pathol
, vol.90
, pp. 123-130
-
-
Bardag-Gorce, F.1
Oliva, J.2
Lin, A.3
Li, J.4
French, B.A.5
French, S.W.6
-
49
-
-
33745227748
-
Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells
-
Meiners S, Ludwig A, Lorenz M, Dreger H, Baumann G, Stangl V, Stangl K. Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med 2006; 40: 2232-2241
-
(2006)
Free Radic Biol Med
, vol.40
, pp. 2232-2241
-
-
Meiners, S.1
Ludwig, A.2
Lorenz, M.3
Dreger, H.4
Baumann, G.5
Stangl, V.6
Stangl, K.7
-
50
-
-
1542328879
-
Proteasome inhibition induces cytokeratin accumulation in vivo
-
Bardag-Gorce F, Vu J, Nan L, Riley N, Li J, French SW. Proteasome inhibition induces cytokeratin accumulation in vivo. Exp Mol Pathol 2004; 76: 83-89
-
(2004)
Exp Mol Pathol
, vol.76
, pp. 83-89
-
-
Bardag-Gorce, F.1
Vu, J.2
Nan, L.3
Riley, N.4
Li, J.5
French, S.W.6
-
51
-
-
79957790904
-
-
The 33rd Annual RSA Scientific Meeting; 2010 Jun 26-30; San Antonio, Texas, USA., Alcoholism: Clinical Experimental Research, Abstract #308
-
Oliva J, Lin A, Li J, French BA, French SW, Bardag-Gorce F. Proteasome inhibitor treatment reduces hepatic steatosis by decreasing lipogenic enzymes gene expression. The 33rd Annual RSA Scientific Meeting; 2010 Jun 26-30; San Antonio, Texas, USA. Alcoholism: Clinical Experimental Research, 2010: 87A, Abstract #308
-
(2010)
Proteasome Inhibitor Treatment Reduces Hepatic Steatosis by Decreasing Lipogenic Enzymes Gene Expression
-
-
Oliva, J.1
Lin, A.2
Li, J.3
French, B.A.4
French, S.W.5
Bardag-Gorce, F.6
-
52
-
-
79957818100
-
The beneficial effects of proteasome inhibitor treatment in alcoholic liver disease
-
Bardag-Gorce F, Oliva J, Li A, Li J, French SW. The beneficial effects of proteasome inhibitor treatment in alcoholic liver disease. FASEB J 2011; 25: 366.9
-
(2011)
FASEB J
, vol.25
, Issue.366
, pp. 9
-
-
Bardag-Gorce, F.1
Oliva, J.2
Li, A.3
Li, J.4
French, S.W.5
|